MRK.BA : Summary for MERCK & CO INC CEDEAR (10 REP 1 - Yahoo Finance

U.S. Markets closed

Merck & Co., Inc. (MRK.BA)

Buenos Aires - Buenos Aires Delayed Price. Currency in ARS
Add to watchlist
98.850.00 (0.00%)
At close: 2:28 PM EST
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close98.85
Bid0.00 x
Ask105.00 x
Day's Range98.85 - 98.85
52 Week Range98.85 - 98.85
Avg. Volume937
Market Cap2.6T
PE Ratio (TTM)50.49
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • American City Business Journalsyesterday

    Tech Data’s board gets more diverse with addition of former Merck executive

    Tech Data Corp. has doubled the number of women on its board of directors. Bridgette Heller, a member of the executive committee of French food products company Danone, was appointed to the Tech Data (TECD) board late last month. Diverse companies are more likely to have financial returns above their national industry medians, and are better able to win top talent and improve their customer orientation, according to management consulting firm McKinsey & Co.

  • Market Realistyesterday

    AbbVie’s Venclexta May Become Promising Multiple Myeloma Therapy

    AbbVie (ABBV) and Roche Holdings (RHHBY) have completed a Phase 1 trial evaluating the use of Venclexta as a therapy for multiple myeloma patients.

  • Market Realistyesterday

    Acute Myeloid Leukemia: Growth Opportuny for AbbVie’s Venclexta?

    AbbVie's (ABBV) Venclexta has been granted FDA breakthrough therapy designation as a first line therapy for patients with acute myeloid leukemia who are ineligible for high-dose chemotherapy.